In this small, yet interesting series, we observe angiogenesis could differentiate pulmonary physiopathology by Covid-19 vs. from viral infections of similar severity (such as influenza). Being quite small, we can hardly consider it universal, or whether it could have clinical impact. Meanwhile, we keep learning about the new virus. Progressive respiratory failure is the main…
EuroPCR 2020 | FABOLUS FASTER: In the Quest for the Fastest, Most Potent Platelet Inhibition
This small study tested the pharmacodynamic effects of several antiplatelet agents. It concluded that tirofiban (Aggrastat) provides “more potent and consistent” inhibition of platelet aggregation compared with cangrelor in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. Thirty minutes after the initiation of treatment, there was a nearly threefold difference between tirofiban and cangrelor…
Olive Oil and Cardiovascular Risk: The Higher the Consumption, the Lower the Risk?
High olive oil intake was associated with lower risk of coronary heart disease and cardiovascular disease in two large prospective cohorts of men and women. The substitution of margarine, butter, mayonnaise, and dairy fat with olive oil can have a significant impact on cardiovascular health. The benefits of olive oil intake have been well studied…
The FDA Approves Ticagrelor for Primary Prevention in High Risk Patients
The FDA has approved the indication of ticagrelor as primary prevention in high risk CAD patients with no history of MI or stroke. The lab producing ticagrelor has informed the FDA has based this decision on the THEMIS study, which included nearly 20,000 patients with stable CAD and type 2 diabetes. This decision has come…
Optimal Intervention Timing for NSTEMI with No Antiaggregant Pre-Treatment
Patients undergoing non-ST elevation MI (NSTEMI) who are not pre-treated with P2Y12 receptor inhibitors will benefit from a very early intervention strategy. The optimal intervention timing for NSTEMI patients is still under debate, despite multiple studies, but the ideal timing had never been tested in patients with no platelet aggregation inhibitor pretreatment. After the surge of…
Estimating the Risk of Infection for Healthcare Personnel
Roughly one out of every 100 healthcare workers at hospitals receiving COVID-19 patients become infected. Statistics are not uniform for all corners of earth, and they do not indicate that being on the front line necessarily entails higher risk. A large analysis conducted in the initial epicenter of the COVID-19 pandemic (Wuhan, China) showed that 110…
SPARCL: Highly Effective Prevention of New Events with Atorvastatin after a Stroke
In patients with recent stroke or transient ischemic attack, the total number of vascular events prevented by atorvastatin was twice as high as the number of prevented index events. In other words, the power of atorvastatin in secondary prevention is far superior to primary prevention. This gigantic reduction, both in index and recurrent events, gives…
Antiaggregation vs. Anticoagulation after Peripheral PCI
The truth is this question has no clear answer and what with do with peripheral stenting is transfer the evidence we have on coronary stenting, given the lack of standards and poor reporting on antithrombotic therapy outcomes in randomized studies on endovascular intervention. Heterogeneity is worse when it comes to venous territory. Some time ago…
Webinar SOLACI – 29/05 – Approach to Antiplatelet Therapy in Acute Coronary Syndrome
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Cerebrovascular Events After TAVR May Be Especially Serious
Stroke events do not seem to be related to valve thrombosis or structural degeneration, but to a higher baseline risk in patients who undergo transcatheter aortic valve replacement (TAVR). About 1 in 20 patients who underwent TAVR experienced a stroke or transient ischemic attack during follow-up. According to this new analysis, the consequences of these events…
ECS Guidelines for COVID-19 Management
One of the first statements in this document points out these are not “regular guidelines” developed after thorough analysis of all the available evidence published since the last update. Instead, they are meant to provide temporary basic management pointers on how to handle different scenarios of cardiac patients in the context of the COVID-19 pandemic.…